Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Argus Health
US Department of Justice
Queensland Health
Boehringer Ingelheim
Accenture
Moodys
Daiichi Sankyo
Dow

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019129

« Back to Dashboard

NDA 019129 describes MAXZIDE-25, which is a drug marketed by Mylan Pharms Inc and is included in one NDA. It is available from seven suppliers. Additional details are available on the MAXZIDE-25 profile page.

The generic ingredient in MAXZIDE-25 is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
Summary for 019129
Tradename:MAXZIDE-25
Applicant:Mylan Pharms Inc
Ingredient:hydrochlorothiazide; triamterene
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 019129
Suppliers and Packaging for NDA: 019129
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129 NDA Mylan Pharmaceuticals Inc. 0378-0460 N 0378-0460-01
MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129 NDA Mylan Pharmaceuticals Inc. 0378-0464 N 0378-0464-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG;75MG
Approval Date:Oct 22, 1984TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;37.5MG
Approval Date:May 13, 1988TE:ABRLD:Yes

Expired US Patents for NDA 019129

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc MAXZIDE-25 hydrochlorothiazide; triamterene TABLET;ORAL 019129-003 May 13, 1988 ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Queensland Health
QuintilesIMS
Cantor Fitzgerald
Julphar
Teva
Argus Health
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.